Search

In the era of staggering speed in development of the novel coronavirus disease (COVID‐19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), we have reviewed the dermatologists' tools at hand for their utility (and potential risks) in patients affected by COVID‐19. This review aims to shed light on the antiviral and proviral potential of drugs routinely used in dermatology to modulate COVID‐19. The literature search included peer‐reviewed articles published in the English language (clinical trials or scientific reviews). Studies were identified by searching electronic databases (MEDLINE and PubMed) from January 1990 to March 2020 and by reference lists of respective articles. Somewhat to our surprise, we have found that several of our drugs widely used in dermatology have antiviral potential. On the other hand, we also frequently use immunosuppressive drugs in our dermatologic patients that potentially pose them at increased risk for COVID‐19. [ABSTRACT FROM AUTHOR]

Dermatology and specialty rotations: COVID-19 may reemphasize the importance of internal medicine Since the first case was identified in Wuhan, China in November 2019, the novel coronavirus (COVID-19) has spread worldwide and affected almost all parts of the globe with unprecedented epidemiological, psychosocial, political, financial, and educational repercussions.1-3 In dire times like this, other specialists including dermatologists have stepped up and volunteered their services to help ease the burden and share the medical workload. In brief, internal medicine rotations should be made mandatory for dermatologists as this foundation may of use not only for our professional routine but also for exceptional healthcare crisis such as COVID-19. [Extracted from the article]

Since the emergence of the new coronavirus disease 19 (COVID‐19) pandemic, there has been a concern for the patients with chronic autoimmune diseases including dermatological conditions over the potential exacerbation of these underlying conditions after infection with severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV2). We performed a systematic review to evaluate presentations, postinfection change in the manifestation, diagnosis, and management of flare‐ups of underlying dermatologic disease in patients with COVID‐19. A total of 17 articles were recovered reporting on flare‐ups of dermatological disease including pemphigus vulgaris, psoriasis, subacute cutaneous lupus erythematosus, acrodermatitis continua of Hallopeau, systemic sclerosis sine scleroderma, and Sézary syndrome (SS). Out of these, psoriasis and alopecia areata were the most common conditions. However, most cases of psoriasis could have been attributed to either antimalarial agents that were initially used for the treatment of COVID‐19 or discontinuation of treatment following SARS‐CoV2 infection. [ABSTRACT FROM AUTHOR]

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19) has been a rising concern since its declaration as a pandemic by the World Health Organization on 11 March 2020. Recently, its association with multiple underlying organs has been identified that includes cardiac, renal, gastrointestinal, nervous systems, and cutaneous manifestations. Cutaneous COVID-19 findings have been supposedly classified into the following categories: vesicular (varicella-like), papulo-vesiculsar, chilblains-like ("COVID toes") maculopapular, and urticarial morphologies. In this review, we aim to focus on the proposed pathophysiology behind the various dermatological manifestations associated with COVID-19 and their associated management. We also included prevalence and clinical features of the different COVID-19-related skin lesions in our review. A comprehensive narrative review of the literature was performed in PubMed databases. Data from case reports, observational studies, case series, and reviews till June 2022 were all screened and included in the review. [ABSTRACT FROM AUTHOR]

Background: The humans have been disproportionately affected by the coronavirus disease (COVID‐19) pandemic. The novel coronavirus or the severe acute respiratory syndrome coronavirus 2 (SARS‐COV2) causing coronavirus disease (COVID‐19) has spread across the globe. Androgens have been suggested to have a role in COVID‐19 pathogenesis. Objective: The objective of this review article is to study the link between androgens and COVID‐19. Methodology: PubMed and Google Scholar search was performed to retrieve literature related to the topic. Review articles, clinical trials, retrospective studies, observational studies, and case–control studies were considered for the review. Results: Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infected men are more inclined to be hospitalized for intensive care unit (ICU) as compared with women. This difference in the ICU admissions provides some clue for possible influence of androgens in the severity of COVID‐19. The contribution of androgen and androgen receptor in COVID‐19 disease and its severity, as well as the numerous medications targeting androgen and its receptor for lowering COVID‐19 disease severity, are discussed in this review. Available literature suggests the role of androgen in the pathogenesis and severity of COVID‐19. Sensitivity for androgen may be an important factor in regulating the severity of COVID‐19 disease. Conclusion: There is a scope for the development of COVID‐19 treatments based on androgen suppression. Clinical trials may furnish pivotal data and add more evidence‐based options for the management of COVID‐19. [ABSTRACT FROM AUTHOR]

We read with great interest a "letter to the Editor" published in the journal of I Dermatologic Therapy i by Gaspari et al,1 who speculated that certain percentage of the asymptomatic population could spread severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) through sexual contact (vaginal, anogenital and orogenital), and anal swab for all coronavirus disease 2019 (COVID-19) patients and those with negative nasopharyngeal swab may be considered. Despite nasopharyngeal testing negativization, COVID-19 patients can persistently result positive on rectal swabs.3 MSM at risk of HIV infection may also continue to engage in risky health behaviors, including ignoring stay-at-home orders, getting in condomless physical contact with possible COVID-19 partners, or have poor access to necessary sexual health clinics, HIV prevention services, and sexually transmitted disease (STD) testing during the current COVID-19 pandemic situation.8 MSM patients younger than 50 years might be at higher risk of COVID-19. COVID-19 patients presented with PR, or known STD, should be enquired about their sexual behavior/preference, and should undergo more than a nasopharyngeal swab before considering negativity of infection. [Extracted from the article]

Introduction: The pandemic caused by the novel coronavirus disease 2019 (COVID‐19) has had an unprecedented impact on the overall health and the global economy. Vaccination is currently the most dependable strategy to end the pandemic, despite the slower‐than‐hoped‐for rollout, particularly for low‐to‐middle‐income countries, and the uncertain duration of protection afforded by vaccination. The spike protein of the virus (immunodominant antigen of the virus) is the main target of the approved and candidate SARS‐CoV‐2 vaccines. This protein binds to the ACE2 receptor of the host cell, initiating the entry of the virus into the cell and the chain of subsequent events ending to Acute Respiratory Distress Syndrome. The safety profile of these vaccines needs is closely assessed. Methods: This comprehensive review includes searching the PubMed, EMBASE, and Web of Science databases using the keywords "coronavirus", "COVID‐19", "vaccine", "cutaneous reactions", "allergic reactions", and "SARS‐CoV‐2". Manual searching of reference lists of included articles augmented the research. The research was updated in June 2021. Results: In this narrative review, we tried to investigate and discuss the cutaneous and allergic reactions related to SARS‐CoV‐2 vaccines currently available in the literature. As a result, although COVID‐19 vaccines can be reported to develop allergic and anaphylactic reactions, especially after m‐RNA vaccines, they remain at a low rate, and it is observed that these reactions may develop more frequently, especially in patients with previous allergies and mast cell disorders. Fortunately, these reactions are generally transient, benign, self‐limited. Conclusion: Although there is still no definitive evidence, as dermatologists, we must be aware of the possibility of cutaneous reactions, newly diagnosed dermatoses, or exacerbation of existing dermatoses that may develop after the COVID‐19 vaccinations. [ABSTRACT FROM AUTHOR]

Introduction: Although the COVID‐19 vaccination is deemed safe, exact incidence and nature if adverse effects, particularly dermatological ones, are still unknown. Objective: To describe the demographic, clinical, morphological characteristics, outcomes, and timing of development of herpes zoster to the various COVID‐19 vaccines. And to identify on whether COVID‐19 vaccine has temporal relationship between development of herpes zoster (HZ). Methods: We have performed a systemic review of articles from PubMed and Embase using MeSH and keywords like "Shingles," "Herpes zoster," "Varicella zoster," "COVID‐19," "Vaccine," "SARS‐CoV‐2." No filters including country of publication, language, type of articles were applied. Individual case report references were filtered for any pertinent cases. Results: A total of 54 cases consisting of 27 male and 27 female patients have been reported. There were cases with known risk factors for herpes zoster, which included age more than 50 years (n = 36), immunological disorders (n = 10), chronic disease (n = 25), metabolic disorder (n = 13), malignancy (n = 4), and psychiatric disorder (n = 2). The mean (SD) period between development of herpes zoster and COVID‐19 vaccination was 7.64 (6.92) days. Majority of the cases were from the high‐income and/or middle‐income countries. 86.27% of the cases of HZ were reported due to mRNA vaccine. Thirty‐six patients 36/45 (80%) developed herpes zoster following the priming dose of COVID‐19 vaccine among those who received mRNA vaccine. Conclusion: We could not establish definite link but there may be possible association between COVID‐19 vaccine and shingles. Large‐scale studies may help to understand the cause‐effect relationship. [ABSTRACT FROM AUTHOR]

Introduction: The various cutaneous manifestations have lately appeared in the setting of COVID‐19. Psoriasis flare‐ups have been reported during a COVID‐19 infection. Case presentation: We present a case of a 32‐year‐old woman with COVID‐19 who presented with generalized pustular psoriasis. She received oral prednisolone, hydroxyzine, and topical clobetasol. The patient received follow‐up two weeks later and found that her lesions were favorably desquamating. Methods: The PubMed, SCOPUS, and ISI Web of Science databases were thoroughly searched for English studies reporting psoriasis flare‐ups following SARS‐CoV‐2 infection. Ten case reports/series were included after screening. Conclusions: Our case report brings awareness to clinicians for the possible cutaneous manifestation of COVID‐19, which should be considered part of the differential diagnoses. [ABSTRACT FROM AUTHOR]

The novel coronavirus disease (COVID‐19) has limited traditional consultation and minimized health care access. Teledermatology (TD) has come to the rescue in this situation by extending consultation for nonessential conditions to the comfort of patient's homes. This limits the risk of exposure of both doctors and patients to the coronavirus (SARS‐CoV‐2). And while there is a reported increase in teleconsultations during the ongoing pandemic, there are some demerits that avert the shift to virtualized health care. The authors conducted an online survey to further understand the hesitancy, limitations, merits, and the demographic of dermatologists who were conducive to TD and these data were analyzed and presented in this article. While TD might never replace physical consultation, it definitely serves an adjunctive role in the post‐COVID era, provided adequate regulatory measures are in place. [ABSTRACT FROM AUTHOR]

A preliminary observation of high frequency of male pattern hair loss among admitted COVID‐19 patients and suggest that androgen expression might be a clue to COVID‐19 severity. [ABSTRACT FROM AUTHOR]

As the new coronavirus disease 2019 (COVID-19) pandemic continues to wreak havoc throughout the globe with ever increasing daily case reports, death totals, and new outbreaks, we are almost becoming numb to these figures.1-3 Amid this onslaught of terrible news, we must look for slivers of hope and silver linings in this black cloud.3-6 One such unseen benefit would be the likely decreasing incidence of malignant melanoma. One of the classic risk factors for melanoma in fair individuals is a history of severe sunburns.7,8 Due to the COVID-19 pandemic, the population has been under "lockdown" to enforce social distancing and prevent further spread of the virus in an effort to contain it. While it is impossible to calculate exact numbers, the incidence of excessive ultraviolet (UV) exposure and harmful sunburns will decrease, leading to a logical decrease in the incidence of future melanoma. [Extracted from the article]

How to manage high-risk asymptomatic COVID-19 carriers; COVID-19 poses a huge threat to public health and to dermatology specialty as well Novel corona virus 2019 (COVID-19) has spread throughout the globe like wildfire since December 2019. Data have shown that a combination of lymphopenia and a high C-reactive protein (CRP) may be sensitive in COVID-19 patients.9A recent study demonstrated that eosinopenia and elevated CRP may facilitate triage of COVID-19 patients in fever clinic.10 This combination should be used to screen asymptomatic but potentially infective patients who have not yet or may never develop symptoms. [Extracted from the article]

The world was put on high alert when an outbreak of a novel coronavirus disease (COVID-19) was declared a pandemic by the World Health Organization (WHO) in early March 2020.1-3 COVID-19 looms as a serious medical crisis inflicting both human and economic suffering.4-6 Before pandemic, dermatologists, plastic surgeons, and other aesthetic practioners were all thriving amid the cosmetic boom. A plethora of laser and light devices for skin resurfacing, hair reduction, scar treatments, skin tightening, and fat reduction has dominated cosmetic dermatology practices worldwide. A psychological barrier and a "wait-and-see" attitude is common for aesthetic dermatology procedures when populations are faced with a massive uncertainty of the type that COVID-19 is presenting to the world. [Extracted from the article]

Simple Summary: The ongoing coronavirus disease-2019 (COVID-19) pandemic shows unprecedented challenges for the worldwide healthcare system. Despite the large clinical data concerning several therapeutic interventions and drug repurposing, results are still either preliminary or lacking adequate-clinical efficiency. Herein, different pharmacoinformatics approaches have been adopted such as molecular docking, ADME properties prediction and all-atom MD simulation to investigate several marine-derived scalarane derivatives as lead candidates against two of the major COVID-19 targets; main protease and Nsp15 endoribonuclease. The presented study clearly illustrates the fitness of the proposed scalarane molecules as promising clinical candidates for further development and future in-vitro/in-vivo studies against SARS-CoV-2. Presently, the world is under the toll of pandemic coronavirus disease-2019 (COVID-19) outbreak caused by SARS-CoV-2. Lack of effective and safe therapeutics has stressed the scientific community for developing novel therapeutics capable of alleviating and stopping this pandemic. Within the presented study, molecular docking, ADME properties and all-atom molecular dynamic (MD) simulation, along with two standard antiviral agents (lopinavir and benzopurpurin-4B), were applied to investigate 15 scalaranes sesterterpenes natural compounds, purified from the Red Sea marine sponge Hyrtios erectus, as potential COVID-19 dual-target inhibitors. Following multi-step docking within COVID-19 main protease and Nsp15 endoribonuclease cavities, nine promising drug-like compounds exhibited higher docking scores as well as better interactions with the target's crucial residues than those of reference ligands. Compounds 2, 6, 11, and 15, were predicted to simultaneously subdue the activity of the two COVID-19 targets. Dynamics behavior of the best-docked molecules, compounds 15 and 6, within COVID-19 target pockets showed substantial stability of ligand-protein complexes as presented via several MD simulation parameters. Furthermore, calculated free-binding energies from MD simulation illustrated significant ligand's binding affinity towards respective target pockets. All provided findings supported the utility of scalarane-based sesterterpenes, particularly compounds 15 and 6, as promising lead candidates guiding the development of effective therapeutics against SARS-CoV-2. [ABSTRACT FROM AUTHOR]